The initial reduction in tumor growth in M-Smo/EedcKO tumors was consistent with previous studies that showed anti-tumor effects of PRC2 disruption using EZH2 inhibitor treatment in models SHH medulloblastoma [22, 59, 60]. Here, EZH2 is linked to neoplasm.